ZEGALOGUE Drug Patent Profile

When do Zegalogue patents expire, and when can generic versions of Zegalogue launch?

Zegalogue is a drug marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in ZEGALOGUE is dasiglucagon hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zegalogue

Zegalogue was eligible for patent challenges on March 22, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 18, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEGALOGUE

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for ZEGALOGUE
What excipients (inactive ingredients) are in ZEGALOGUE?	ZEGALOGUE excipients list
DailyMed Link:	ZEGALOGUE at DailyMed

See drug prices for ZEGALOGUE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEGALOGUE

Constraining patent/regulatory exclusivity:

NEW PATIENT POPULATION

NDA:

214231

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZEGALOGUE

Drug Class	Antihypoglycemic Agent
Mechanism of Action	Glucagon Receptor Agonists
Physiological Effect	Increased Glycogenolysis

US Patents and Regulatory Information for ZEGALOGUE

ZEGALOGUE is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW PATIENT POPULATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		DISCN	Yes	No
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		DISCN	Yes	No
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		DISCN	Yes	No
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		DISCN	Yes	No
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		DISCN	Yes	No			Y	Y
Zealand Pharma	ZEGALOGUE	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-001	Mar 22, 2021		DISCN	Yes	No

International Patents for ZEGALOGUE

When does loss-of-exclusivity occur for ZEGALOGUE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

India

Israel

Japan

Malaysia

Mexico

Netherlands

New Zealand

Philippines

Poland

Singapore

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEGALOGUE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	091866
Australia	2013295035
Brazil	112015001451
Canada	2878991
China	104662038
China	109456400

Supplementary Protection Certificates for ZEGALOGUE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2875043	301294	Netherlands		PRODUCT NAME: DASIGLUCAGON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, ZOALS DASIGLUCAGON HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/24/1829 20240725
2875043	CR 2024 00043	Denmark		PRODUCT NAME: DASIGLUCAGON ELLER ET FARMACEUTISK SALT ELLER SOLVAT DERAF, SASOM DASIGLUCAGONHYDROCHLORID; REG. NO/DATE: EU/1/24/1829 20240725
2875043	122024000057	Germany		PRODUCT NAME: DASIGLUCAGON IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1829 20240724
2875043	C20240034	Finland
2875043	24C1043	France		PRODUCT NAME: DASIGLUCAGON DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/24/1829 20240725
2875043	2490313-0	Sweden		PRODUCT NAME: DASIGLUCAGON OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, SUCH AS DASIGLUCAGON HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1829 20240724

Zegalogue Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Zegalogue, Zealand Pharma’s dasiglucagon rescue treatment for severe hypoglycemia, has established a commercial position in the U.S. glucagon market but remains a small product relative to the company’s obesity and rare-disease pipeline. Its growth depends on broader adoption of ready-to-use glucagon, payer access, diabetes technology partnerships, and conversion from traditional emergency glucagon kits. The product has regulatory exclusivity and formulation-related patent protection, but faces competition from Lilly’s Baqsimi and generic injectable glucagon.

What is Zegalogue and who owns it?

Zegalogue is a ready-to-use, aqueous glucagon injection containing dasiglucagon, a stable glucagon analog. Zealand Pharma developed and commercializes the product in the United States.

Item	Details
Brand	Zegalogue
Active ingredient	Dasiglucagon
Company	Zealand Pharma A/S
U.S. approval	March 22, 2021
FDA indication	Treatment of severe hypoglycemia in adults and pediatric patients aged 6 years and older with diabetes
Dosage forms	Prefilled syringe and autoinjector
Therapeutic category	Emergency glucagon rescue
Primary market	United States
Regulatory pathway	New drug application
Key competitor	Baqsimi, nasal glucagon, Eli Lilly
Other competitors	Generic injectable glucagon emergency kits

The product is differentiated from traditional glucagon kits because it is supplied as a ready-to-use liquid. Traditional kits generally require reconstitution before injection, creating a usability disadvantage during an emergency. Baqsimi is also ready to use but is administered intranasally rather than by injection. [1]

What is Zegalogue’s FDA regulatory status?

The FDA approved Zegalogue for severe hypoglycemia in March 2021. The approval covers adults and children aged at least six years. Zealand later received approval for an expanded prefilled syringe presentation, giving the company two delivery formats: an autoinjector and a prefilled syringe. [2]

Regulatory milestone	Date
U.S. NDA approval	March 22, 2021
Commercial launch	2021
Pediatric population at approval	Six years and older
Product presentations	Autoinjector and prefilled syringe
FDA therapeutic area	Diabetes and hypoglycemia rescue

Zegalogue is not a biologic, so biosimilar substitution is not the relevant competitive threat. The principal regulatory threat is an abbreviated new drug application for a generic or follow-on glucagon product, combined with substitution by Baqsimi or other ready-to-use rescue products.

How large is the severe hypoglycemia rescue market?

The addressable market is concentrated in insulin-treated diabetes. Severe hypoglycemia is most relevant to people with type 1 diabetes and people with advanced type 2 diabetes who use intensive insulin regimens. Prescribing is influenced by diabetes guidelines, emergency preparedness, caregiver education, insurance coverage, and the presence of children or adults at high risk of hypoglycemia.

The market has three structural segments:

1. Traditional reconstituted glucagon emergency kits.
2. Ready-to-use injectable glucagon, including Zegalogue.
3. Ready-to-use nasal glucagon, led by Baqsimi.

Ready-to-use products have expanded the market beyond patients who routinely carry emergency kits. They also compete for replacement prescriptions when older kits expire, are lost, or are used.

Zegalogue’s commercial opportunity is constrained by the fact that glucagon is an intermittent rescue product. It is prescribed for emergency readiness rather than daily treatment. Prescription volume can therefore grow without producing revenue comparable to chronic diabetes medicines.

How does Zegalogue compare with Baqsimi and generic glucagon?

Product	Manufacturer	Delivery	Main commercial advantage	Main limitation
Zegalogue	Zealand Pharma	Autoinjector or prefilled syringe	Ready-to-use liquid glucagon; injection familiarity	Smaller commercial scale and limited geographic reach
Baqsimi	Eli Lilly	Nasal powder	Needle-free administration	Nasal administration may be unsuitable in some situations
Generic glucagon kits	Multiple manufacturers	Reconstituted injection	Low acquisition cost	Preparation steps and lower convenience
Traditional branded kits	Multiple manufacturers	Reconstituted injection	Established clinical familiarity	Administration complexity

Zegalogue competes most directly with Baqsimi on convenience rather than molecular mechanism. Both products reduce preparation steps compared with older glucagon kits. Baqsimi’s needle-free format is attractive for caregivers and schools. Zegalogue’s injection route may be preferred by some clinicians and patients because it uses the conventional glucagon administration pathway.

Price and reimbursement are decisive. A ready-to-use product can command a premium only if payers cover it without restrictive prior authorization or if manufacturers provide meaningful savings programs.

What has driven Zegalogue’s financial trajectory?

Zegalogue revenue has been a developing commercial stream rather than the principal driver of Zealand Pharma’s valuation. Zealand’s overall financial trajectory has been shaped by licensing income, milestone payments, royalties, and pipeline assets, particularly in obesity and gastrointestinal disease. Zegalogue contributes recurring product revenue but does not have the scale of a major chronic-care product.

Public company filings show that Zegalogue sales increased after launch as Zealand expanded payer coverage, pharmacy distribution, and awareness of ready-to-use glucagon. The product’s revenue profile is best characterized as gradual adoption rather than rapid market displacement.

Financial factor	Effect on Zegalogue
U.S. launch in 2021	Created a new recurring product-revenue stream
Ready-to-use formulation	Supports premium positioning versus reconstituted kits
Baqsimi competition	Limits pricing power and share expansion
Generic glucagon	Creates persistent low-cost substitution pressure
Diabetes technology adoption	Increases awareness of severe hypoglycemia preparedness
Payer restrictions	Can delay prescriptions and reduce net price
Limited market geography	Keeps product revenue below the scale of global diabetes drugs
Manufacturing scale	Affects gross margin and supply economics

Zealand reports product sales within its financial disclosures, but company-level revenue also includes license revenue and milestone payments. Zegalogue should therefore be evaluated as a product-growth asset, not as a proxy for total Zealand Pharma performance. [3]

What is the expected revenue trajectory for Zegalogue?

The most likely trajectory is moderate, durable growth followed by a mature rescue-market profile. The key commercial stages are:

2021 to 2022: market establishment

The launch period focused on formulary access, distribution, patient support, and physician awareness. Early sales were limited by the need to establish a new brand in a market already served by established glucagon products.

2023 to 2025: share capture and category expansion

Growth depends on conversion from traditional glucagon kits and increased use of ready-to-use products. School systems, caregivers, emergency preparedness programs, and endocrinology practices are important channels.

Zegalogue can gain share if Zealand improves pharmacy availability, reduces patient out-of-pocket costs, and maintains reliable supply. Baqsimi remains the strongest branded competitor, while generic kits set a ceiling on price.

2026 onward: mature branded rescue product

At maturity, revenue will depend on refill rates, replacement prescriptions, insurance coverage, and product differentiation. A major acceleration would require a new indication, a broader pediatric label, international commercialization, or integration with diabetes monitoring and automated insulin-delivery systems.

When does Zegalogue lose regulatory exclusivity?

Zegalogue received orphan-drug designation for the treatment of severe hypoglycemia associated with diabetes. Orphan-drug exclusivity generally lasts seven years from approval and prevents approval of the same drug for the same indication during that period, subject to statutory exceptions. The relevant period is expected to run until March 2028, although the precise end date depends on the FDA’s orphan-exclusivity record. [4]

Zegalogue may also benefit from five-year new chemical entity exclusivity if FDA records classify dasiglucagon as eligible for that protection. NCE exclusivity would generally expire in 2026, but orphan exclusivity would remain the more important regulatory barrier for the approved orphan indication.

Regulatory exclusivity does not prevent all competitive products. It does not block products that FDA considers sufficiently different, such as an alternative glucagon formulation or a different route of administration, unless the relevant approval would legally rely on protected data or fall within the same exclusivity scope.

What patents protect Zegalogue?

Zegalogue’s protection is based primarily on composition, formulation, stability, and drug-delivery claims. The commercial value of the estate depends on whether listed patents cover the approved product as sold, not merely whether they describe glucagon chemistry broadly.

Known U.S. patent protection associated with dasiglucagon and liquid glucagon formulations includes patents directed to stable glucagon compositions and related use or formulation concepts. The FDA Orange Book should be used as the controlling source for current listed patents, expiration dates, pediatric adjustments, and any changes in listing status. [5]

Protection category	Commercial relevance
Dasiglucagon composition	Can restrict identical active-ingredient products
Stable aqueous formulation	Protects the ready-to-use liquid presentation
Device and presentation	May limit copying of the autoinjector or prefilled syringe
Method of treating severe hypoglycemia	Can create use-code barriers for labeled indications
Manufacturing process	May raise development and scale-up costs for competitors
Orphan exclusivity	Delays approval of the same drug for the same indication

Patent strength is likely strongest around the finished, ready-to-use product rather than around glucagon itself. Glucagon is an established hormone, and generic competitors can avoid certain claims by using different formulations, devices, or administration methods.

Are Paragraph IV challenges likely for Zegalogue?

Paragraph IV risk is real but depends on the Orange Book listing and the timing of generic development. A generic applicant can challenge listed patents by certifying that the patents are invalid, unenforceable, or not infringed. Filing a Paragraph IV certification can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval. [6]

The most likely challenge targets are:

• Stable aqueous formulation claims.
• Product-by-process or manufacturing claims.
• Device claims covering the prefilled syringe or autoinjector.
• Method-of-use claims for severe hypoglycemia.
• Any patent with an expiration date materially later than orphan exclusivity.

An ANDA applicant may also avoid some patents by pursuing a different formulation or device. That strategy would reduce the scope of a patent dispute but could require additional clinical, device, or human-factors work.

What patent litigation and settlements affect Zegalogue?

Zegalogue has not become the subject of a high-profile generic patent dispute comparable to major chronic medicines. The principal litigation risk remains prospective: an ANDA filing could lead to a Hatch-Waxman case once regulatory exclusivity and commercial opportunity justify the development cost.

A settlement could include a licensed generic launch date, royalties, supply arrangements, or restrictions tied to specific formulations. No material public settlement should be treated as a confirmed market event unless it appears in a court docket, SEC filing, FDA record, or Zealand disclosure.

What manufacturing and intellectual-property barriers exist?

Manufacturing is a meaningful barrier because Zegalogue is a peptide drug supplied in a stable liquid formulation. Competitors must reproduce the active ingredient, maintain chemical and physical stability, meet sterile manufacturing standards, and qualify a delivery device.

The main barriers are:

• Peptide synthesis or recombinant production capability.
• Control of impurities and degradation products.
• Long-term stability in a ready-to-use liquid.
• Sterile fill-finish capacity.
• Device reliability and dose delivery.
• Human-factors validation.
• Packaging and cold-chain or temperature-control requirements.
• Freedom to operate around formulation and device patents.

These barriers favor branded products over simple copies, but they do not eliminate generic competition. A well-funded generic manufacturer with an alternative formulation can still enter if it develops a legally and technically distinct product.

How does Zegalogue compare with Zealand Pharma’s broader portfolio?

Zegalogue provides commercial validation and recurring revenue, but Zealand Pharma’s valuation is more sensitive to its obesity and peptide pipeline than to glucagon rescue sales. The company’s strategic priority has shifted toward assets with larger chronic-treatment markets and licensing potential.

Asset characteristic	Zegalogue	Obesity and metabolic pipeline
Revenue model	Product sales	Potential product sales, milestones, royalties, or licensing
Treatment frequency	Emergency, intermittent	Chronic or repeated dosing
Market size	Specialty rescue market	Large obesity and metabolic markets
Competitive intensity	Baqsimi and generic glucagon	Large pharmaceutical and biotechnology competitors
Commercial maturity	Launched product	Development and partnering dependent
Valuation sensitivity	Moderate	Potentially high, based on clinical and deal outcomes

Zegalogue remains strategically useful because it gives Zealand an approved U.S. commercial product and commercial infrastructure. Its financial contribution is less important than the company’s large pipeline assets, but its revenue is less dependent on future clinical readouts.

What generic launch scenarios exist for Zegalogue?

Scenario 1: No near-term generic entry

The branded product retains the market through orphan exclusivity, patent enforcement, and limited generic economics. This supports continued moderate revenue growth.

Scenario 2: Authorized or licensed generic

Zealand or a commercial partner licenses a lower-priced version. This could protect overall franchise volume but would reduce net price and branded revenue.

Scenario 3: Formulation-specific generic entry

A competitor launches a product that avoids one or more formulation or device claims. The entrant initially targets price-sensitive payers and high-volume channels.

Scenario 4: Alternative ready-to-use glucagon product

A competitor enters with a differentiated nasal, autoinjector, or other delivery system. This would compete without necessarily relying on dasiglucagon and could weaken Zegalogue’s pricing power before patent expiry.

What is the commercial outlook for Zegalogue?

Zegalogue has a credible but bounded commercial outlook. The product’s advantages are practical: ready-to-use administration, two delivery presentations, and a recognized clinical need. Its limitations are market size, branded competition, payer sensitivity, and the availability of low-cost generic glucagon kits.

The strongest growth levers are improved reimbursement, broader caregiver and school adoption, stronger diabetes-device integration, and international commercialization. The largest downside risks are formulary exclusion, net-price erosion, weak refill rates, and a generic or competing ready-to-use product entering before Zealand reaches full commercial maturity.

Key Takeaways

• Zegalogue is Zealand Pharma’s ready-to-use dasiglucagon rescue product for severe hypoglycemia.
• The FDA approved it in March 2021 for adults and children aged six years and older.
• Its closest branded competitor is Eli Lilly’s Baqsimi nasal glucagon.
• Generic reconstituted glucagon kits create a persistent price ceiling.
• Orphan-drug exclusivity is expected to provide protection through approximately March 2028, subject to the FDA record.
• The main intellectual-property value lies in the stable liquid formulation, delivery presentations, and related use claims.
• Zegalogue revenue is strategically useful but is unlikely to drive Zealand Pharma’s valuation as strongly as its obesity and metabolic pipeline.
• The most probable financial path is moderate growth, followed by maturation rather than blockbuster expansion.
• Paragraph IV risk is prospective and depends on Orange Book listings, patent scope, and the economics of generic development.
• Biosimilar risk does not apply because Zegalogue is a peptide drug rather than a biologic.

FAQs About Zegalogue Market and Patent Risk

Is Zegalogue a biologic or a generic drug?

Zegalogue is a branded peptide drug containing dasiglucagon. It is not a biosimilar. A competing product would generally use an ANDA, NDA, or another applicable FDA pathway rather than the biosimilar pathway.

Does Zegalogue require refrigeration?

Storage requirements depend on the specific presentation and current prescribing information. Product handling should follow the FDA-approved label and manufacturer instructions.

Is Zegalogue more effective than Baqsimi?

Both products are approved for severe hypoglycemia. The main difference is administration: Zegalogue is injected, while Baqsimi is administered nasally. Product selection depends on clinical preference, caregiver ability, device familiarity, and payer coverage.

Can Zegalogue be used in children younger than six?

The FDA-approved indication covers patients aged six years and older. Use outside the approved age range requires clinical judgment and is not part of the approved label.

Will Zegalogue become available outside the United States?

International expansion depends on Zealand Pharma’s regulatory filings, commercial partnerships, and country-specific approvals. U.S. approval does not establish automatic marketing authorization in other jurisdictions.

References

1. U.S. Food and Drug Administration. (2021). FDA approves Zegalogue for severe hypoglycemia in adults and pediatric patients with diabetes. FDA.

2. Zealand Pharma A/S. (2021-2024). Annual reports and corporate product disclosures. Zealand Pharma.

3. Zealand Pharma A/S. (2023). Annual report 2023. Zealand Pharma.

4. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. FDA Office of Orphan Products Development.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Amendments and requests for final approval. FDA.

DrugChatter Q&A for ZEGALOGUE

Zegalogue (autoinjector)?
What is zegalogue used for?
Is zegalogue safe?